Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The direct medical costs of alpha(1)-antitrypsin deficiency.

Chest - 1 Mar 2001

Mullins C D, Huang X, Merchant S, Stoller J K

Abstract excerpt

BACKGROUND: For individuals with emphysema because of severe alpha(1)-antitrypsin deficiency, specific therapy called IV augmentation therapy has been available since 1989. Such therapy consists of IV infusion of pooled human plasma alpha(1)-antiprotease. METHODS: To assess the direct medical cos...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to alpha 1-Antitrypsin
Share to alpha 1-Antitrypsin Deficiency
Share to Health Care Costs

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Infusions, Intravenous

Share to Phenotype

Share to Pulmonary Emphysema

Share to Registries

Share to Surveys and Questionnaires

Source

Identifiers

PMID: 11243952
DOI: 10.1378/chest.119.3.745

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-11243952-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The direct medical costs of alpha(1)-antitrypsin deficiency.PMID 11243952Read ↗

Major components of the direct medical costs of alpha1-antitrypsin deficiency.Semantic proximity Read ↗

Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data.Semantic proximity Read ↗

Medical Costs of Alpha-1 Antitrypsin Deficiency-Associated COPD in the United StatesSemantic proximity Read ↗

The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency.Semantic proximity Read ↗

Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor.Semantic proximity Read ↗

Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank.Semantic proximity Read ↗

[Long-term therapy of alpha 1-antitrypsin-deficiency-associated pulmonary emphysema with human alpha 1-antitrypsin].Semantic proximity Read ↗

Alpha-1 Antitrypsin Augmentation TherapySemantic proximity Read ↗

Alpha-1 antitrypsin (AAT) augmentation therapy in individuals with the PI*MZ genotype: a pro/con debate on a working hypothesis.Semantic proximity Read ↗

Augmentation Therapy for Severe Alpha-1 Antitrypsin Deficiency Improves Survival and Is Decoupled from Spirometric Decline-A Multinational Registry Analysis.Semantic proximity Read ↗

Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence.Semantic proximity Read ↗

A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.